Active Solid Malignancy, Myeloma, Non-Hodgkin's Lymphoma
Conditions
Keywords
PET Scan, 124I-PUH71, 10-139
Brief summary
The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body & inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting tumors with scanner machines.
Interventions
DRUGPET Imaging using 124 IPUH71
A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\ 7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
Sponsors
Samus Therapeutics
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma (histology confirmed by MSKCC Department of Pathology) * Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or other tumor response criteria from an MSKCC IRB-approved clinical research protocol. * This does not apply to patients with myeloproliferative neoplasm. The presence of active myeloproliferative neoplasm will be determined by applicable disease specific diagnostic criteria and patient assessment by the patient's oncologist and trial investigators (eg, manifestations of active MPN such as splenomegaly, abnormal blood counts, etc). * Age between 18-90 * Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential * No breast-feeding
Exclusion criteria
* Previous allergic reaction to contrast medium. * Hypersensitivity to iodide products. * Known hyperthyroidism Hepatic: * Bilirubin \> 1.5 x institutional upper limit of normal (ULN) * AST/ALT \>2.5 x ULN * Albumin \< 2 g/dl * GGT \> 2.5 x ULN IF Alkaline phosphatase \> 2.5 x ULN. Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min. * Positive serum pregnancy test for females * Acute major illness (e.g., infection, unstable cardiovascular condition, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To study the pharmacokinetics | 2 years | of 124I-PUH71 in patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To study the metabolism | 2 years | of 124I-PUH71 in patients with solid malignancy, myeloproliferative neoplasm myeloma and/or lymphoma. |
| To study the biodistribution | 2 years | of 124I-PUH71 in patients with solid malignancy, myeloproliferative neoplasm myeloma and/or lymphoma. |
| To study the radiation dosimetry | 2 years | of 124I-PUH71 in patients with solid malignancy, myeloproliferative neoplasm myeloma and/or lymphoma. |
Countries
United States
Outcome results
None listed